Legend Biotech Stock News

Legend Biotech Corporation (NASDAQ:LEGN) has seen 1.44 million shares traded in the last trading session. The company, currently valued at $6.38B, closed the last trade at $48.68 per share which meant it gained $1.7 on the day or 3.62% during that session. The LEGN stock price is -19.15% off its 52-week high price of $58.00 3.62 Gain Turns Legend Biotech Corporation (LEGN) Into A Winning Stock For Investors Read More »

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares (ADSs), each representing two ordinary shares, at a public offering price of $40.00 per ADS, for total gross proceeds of approximately $300.0 mi

The stock price of Legend Biotech Corporation (NASDAQ: LEGN) increased by over 4% during intraday trading today. This is why it happened.

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel (cilta-cel) in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Cilta-cel is an investigational B-cell

2 of note is that the 20 hour changed directions on legn; it is now pointing up. The post Legend Biotech Corp (LEGN): Price Now Near $48.37; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .

Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seekin

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene autoleucel (cilta-cel) by its collaboration partner, Janssen Pharmaceutical K.K. (Janssen). Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen rec

Legend Biotech (NASDAQ:LEGN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. […]

Legend Biotech (NASDAQ:LEGN) announced its quarterly earnings data on Monday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.35) by ($0.08), MarketWatch Earnings reports. Legend Biotech had a negative net margin of 343.40% and a negative return on equity of 101.68%. NASDAQ:LEGN traded up $3.30 during mid-day []

Related Stocks: PACB , BYND , NTLA , NRIX , NSTG , LSPD , DSGX , LEGN , RKLB , BRKR , ASTR , ACAD , SRAC , MCRB ,

Biopharmaceutical company Legend BioTech (LEGN) hit a new 54-week high this Tuesday, up 103.4% this year.  LEGN is a multinational biopharmaceutical company primarily engaged in the discovery and dev

Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.